Vidac Pharma News
15 articles
U.S. grants Vidac Pharma patent offering broad protection of mode of action underlying its oncology drug candidates
Vidac Pharma Holding PLC announced that the United States Patent and Trademark Office (USPTO) has issued a broad patent protecting the mode of action of its oncology and onco-dermatologic therapeutic candidates. This patent covers the use of Vidac’s new chemical entities to reverse the hyperglycolytic metabolism of cancer cells, potentially halting cancer cell proliferation and restoring apoptosis. Vidacs product candidates, VDA-1275 and VDA-1102, are in various stages of clinical trials and have shown promising results in treating cancer. This patent strengthens Vidacs position in the market by providing exclusive rights to this novel treatment approach in the U.S.
Investment
Vidac Pharma publishes results of next-generation drug candidate tests in human and murine tumor models
Vidac Pharma Holdings Plc, a clinical-stage oncology biopharmaceutical company, has announced promising results from its study with VDA-1275 in multiple mouse cancer and human cellular organoid models of solid tumors. The study showed that VDA-1275 showed statistically significant efficacy as a monotherapy, as well as synergistic effects in combination with two standard-of-care cancer treatments. The drug also induced an immunologic response. The companys CEO, Max Herzberg, stated that these results provide evidence that VDA-1275 might in the future be used as a standalone drug, or in combination therapy that might allow more effective and safer treatment of patients with solid tumors.
Investment
Vidac Pharma receives US patent office Notice of Allowance for crucial compounds in its cancer drug candidates
Vidac Pharma Holding PLC, a clinical-stage oncology biopharmaceutical company, has announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a group of molecules that can trigger an immune response across a wide range of cancers. The molecules are crucial compounds in Vidac’s two drug candidates, VDA-1102 and VDA-1275. The patent is a significant step in Vidacs efforts to develop a new class of cancer drugs. The companys molecules have the ability to dislodge the Hexokinase-2 (HK2) enzyme from the mitochondrial VDAC pores, which reverses the abnormal metabolism of cancer cells, restores immune-supportive conditions, and restores programmed cell death.
Investment
Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate
Vidac Pharma Holding PLC, a clinical-stage oncology biopharmaceutical company, has received a Notice of Allowance from the Japanese Patent Office for the composition and methods of use for its VDA-1275 drug candidate. The drug has shown promising effects in preclinical studies, including direct effects against a variety of tumors in animal trials and powerful synergistic effects in combination with two widely used types of chemotherapy in human liver organoids. The company plans to publish these results in a peer-reviewed publication.
Investment
Vidac Pharma secures approval for next phase of clinical study of lead asset in Cutaneous T-Cell Lymphoma
Vidac Pharma Holdings Plc, a clinical-stage oncology biopharmaceutical company, has received approval from the Helsinki Committee of the Beilinson Hospital in Israel to proceed with the second stage of a Phase 2a clinical trial of its lead drug candidate VDA-1102 in Mycosis Fungoides (MF), a form of Cutaneous T-Cell Lymphoma (CTCL). The company reported positive interim results based on 50% of subjects in January and now expects the second stage of the trial to take 3 to 4 months, with final results expected in the fourth quarter of the year.
Customers
Vidac Pharma presents high efficacy in multiple solid tumor models for its next-generation cancer drug candidate and synergy with standard-of-care treatment in liver cancer organoids
Vidac Pharma Holding PLC, a clinical-stage oncology biopharmaceutical company, has announced promising results for its drug candidate VDA-1275 in multiple mouse cancer and human cellular organoid model of solid tumors. The drug showed significant efficacy as a monotherapy and in combination with two standard-of-care cancer treatments. The company will present these findings on 28 February, at the Sachs 17th Annual European Life Sciences CEO Forum. The company is also planning to publish the results in a peer-reviewed publication.
InvestmentCustomers
Vidac Pharma reports positive interim Phase 2a data in orphan disease cutaneous T-cell lymphoma (CTCL) with lead asset VDA-1102
Vidac Pharma Holdings Plc, a clinical-stage oncology biopharmaceutical company, has announced positive interim results from a Phase 2a trial of its lead drug candidate VDA-1102 in treating Mycosis Fungoides, a rare form of Cutaneous T-Cell Lymphoma. The interim analysis showed an Objective Response Rate of 56%, with 22% complete response and 34% partial response. These results compare favorably to the standard of care of mechlorethamine. The companys approach of attacking cancer at its core has shown substantial therapeutic potential. The interim results come from more than 50% of planned patients in an open-label within-subject placebo-controlled study.
Customers
Vidac Pharma to conduct Phase 2b study for actinic keratosis therapeutic candidate VDA-1102 with CentroDerm
Vidac Pharma Holding PLC is preparing for a Phase 2b trial of its lead candidate VDA-1102, a treatment for actinic keratosis (AK), a common type of non-melanoma skin cancer. The company has partnered with CentroDerm GmbH, a leading dermatology research institute, and Forschungsdock Gmbh, a CRO, to conduct the study. VDA-1102 is part of Vidac Pharmas family of small molecules that modulate the Hexokinase 2 (HK2) enzyme, which is known to promote cancer cell proliferation and resist treatment. The upcoming trial aims to refine inclusion criteria and endpoints for advanced AK.
Partners
Vidac Pharma reports in vitro results showing VDA-1275 compatible with classical chemotherapy
Vidac Pharma Holding PLC, a clinical-stage oncology biopharmaceutical company, has announced positive results from an in vitro study of VDA-1275, a small molecule that targets cancer cell metabolism. The study found that VDA-1275 was effective in suppressing cancer cells, both as a standalone treatment and in combination with chemotherapeutic agents. The drug, which was discovered through AI analysis, has the potential to hinder disease development across multiple forms of cancer due to its unique targeting of a key metabolic feature unique to cancer cells. The company plans to continue studying VDA-1275s potential in combination with various chemotherapeutic agents.
InvestmentExpand
Vidac Pharma will participate to the HTID5 as a fully sponsored guest speaker
Vidac Pharma Holdings Plc. has been chosen as one of the laureates of the Prize for Innovation and will participate in the HTID-5 conference in Paris. The conference is a gathering of innovative companies, investors, and key speakers in the Healthtech industry. Vidac Pharma is a clinical stage biopharmaceutical company focused on developing medicines for oncologic and dermatologic diseases. The company expects to present advancements in their anti-cancer drug candidates at the conference.
Partners
Vidac Pharma to list on Hamburg Stock Exchange
Vidac Pharma, an Israeli clinical stage oncology drug developer, plans to list on the Hamburg Stock Exchange. The company has reached an agreement with GEM Global Yield LLC SCS for a share subscription facility of up to €20 million. The listing on the Hamburg Stock Exchange will provide access to trading on other European stock exchanges. Vidac Pharma aims to use the funds to complete its clinical trial and build relationships with retail and institutional investors in Europe. The companys valuation for the agreement and listing is €60 million. Vidac Pharma is developing a drug based on plant hormones that have shown anti-cancerous activity in trials. The drug targets the Warburg effect, a mechanism used by cancer cells to consume more sugar. The company has discovered a way to intervene in this mechanism and activate cell self-elimination mechanisms.
Public Trading
Vidac Pharma Secures EUR 20m Capital Commitment From GEM
Vidac Pharma has signed an agreement with GEM Global Yield for a EUR 20 million capital commitment. The funding will be used to progress the clinical development of Vidacs lead product and for developing additional products from the companys proprietary HK2-focused discovery platform. Vidac aims to develop anti-cancer drugs based on restoring normal cellular metabolism. The funding and becoming a public entity will help Vidac continue the development of drugs based on their novel anti-cancer paradigm.
Investment
Vidac Pharma Announces Initiation of Phase 2b Clinical Trial of VDA-1102 Ointment in Patients with Actinic Keratosis
Israeli startup Vidac Pharma raises $9m
Israeli startup Vidac Pharma has closed a $9 million Series A financing round led by Israel Biotech Fund. The funds will be used for a Phase II clinical trial of its dermatological ointment to treat actinic keratosis. Existing investors, including Mivtach Shamir Holdings, also participated in the financing. Vidac Pharma plans to advance the development of its lead product, VDA-1102 ointment, and progress its pipeline of novel therapeutics into clinical development. The company aims to develop first-in-class medicines for oncologic and onco-dermatologic diseases by targeting the cancer-specific VDAC/HK2 system without affecting healthy tissue.
Investment
ViDAC Pharma Value Proposition
